Understanding the type of proteins that specific cancer cells produce can be useful in the identification and treatment of those cancers, but it is unknown to what degree protein expression of pediatric brain cancers are under germline genetic control. Using the Pediatric Brain Tumor Atlas, researchers aim to identify, compare, and contrast variations in and mechanisms for protein expression across many individual brain cancer types. This will serve as an important resource on the genetic control of protein expression, further guiding medical professionals on drug response and clinical outcomes.
What are the goals of this project?
Researchers seek to fill the current knowledge gap on the impact of germline mutations on protein expression in pediatric brain cancers.
What is the impact of this project?
With a better understanding of the mechanisms controlling germline protein expression in each cancer type, researchers and medical professionals will pave the way for new targeted therapies.
Why is the CBTN request important to this project?
This project requires a broad dataset across many brain cancer types and the Pediatric Brain Tumor Atlas will provide researchers with the information necessary for comprehensive analysis.
The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas
Sebastian Waszak, PhD
My lab focuses on precision medicine for children, adolescents, and young adults with cancer; in particular children with brain tumours. We combine approaches from population genomics, cancer genomics, and systems genetics to understand the genetic basis of cancer, the somatic evolution of cancer ce
University of Oslo
Javad Nazarian, PhD, MSc
I am an investigator at the Center for Genetic Medicine in Children’s National Hospital in Washington, D.C., and an assistant professor in Integrative Systems Biology at the George Washington University. I received my PhD from the George Washington University in Genetics in 2005. My dissertation res
Children’s National Hospital
Adam Resnick, PhD
Adam Resnick is the Director of Data Driven Discovery in Biomedicine (D3b) at Children’s Hospital of Philadelphia (CHOP) responsible for leading a multidisciplinary team to build and support a scalable, patient-focused healthcare and educational discovery ecosystem on behalf of all children. He is a
Children’s Hospital of Philadelphia
University of Oslo
Center for Molecular Medicine Norway (NCMM)
Children’s National HospitalJoined on
Each year, the Brain Tumor Institute at Children’s National evaluates more than 100 new patients with brain tumors, and is recognized as a world leader in childhood brain tumor care and research. Children’s National has pioneered novel pediatric brain tumor therapies, including new molecularly-targe
Children’s Hospital of PhiladelphiaJoined on
Operations Center for the Children’s Brain Tumor Tissue Consortium, the Children’s Hospital of Philadelphia (CHOP) is currently ranked 1st nationally for their Pediatric Cancer Program by U.S. News & World Report. CHOP’s Biobank is home to the CBTTC’s pediatric brain and CNS tumor biorepository; the